Oncology Insight Report
A peer insight report on referral timing, manufacturing delay, toxicity confidence, evidence gaps, community access and priorities for the next phase of CAR-T and TIL delivery.
Audience: Medical and Hematologic Oncologists
Countries: 6
Survey records: 64
-Hero findings
– Quick Read — Key Findings
The full report maps clinical urgency, evidence gaps, referral confidence, operational barriers and the priorities oncologists want the field to solve next.
CAR-T therapy has established a major role in several blood cancers, while TIL therapy crossed an important solid-tumor milestone with the 2024 FDA approval of lifileucel for advanced melanoma. The treatment model is powerful but operationally demanding because a patient’s own cells must be collected, manufactured or expanded, and returned for treatment.
The National Cancer Institute notes that the laboratory expansion phase in T-cell transfer therapy can take weeks. That time requirement makes patient selection, referral timing, disease control and center coordination part of the clinical effectiveness of the pathway, not merely administrative details.
The MDForLives survey captures that operational reality. Oncologists focus heavily on when to refer, whether the patient can safely wait, how evidence translates outside trials, and how to broaden cellular therapy beyond specialized centers and current disease settings.
Selected external context: National Cancer Institute, T-cell Transfer Therapy; National Cancer Institute, Lifileucel First Cellular Therapy Approved for Cancer; National Cancer Institute, Lifileucel
MDForLives Research Interpretation
29.4% identify finding eligible patients at the optimal time before rapid progression as the greatest unmet need, followed by 21.6% who prioritize expanding access and efficacy in solid tumors. Toxicity management and long-term durability each receive 15.7%.
What the pattern suggests: The leading concern is not simply whether a cellular therapy exists. It is whether the right patient reaches the pathway early enough to benefit from it.
Why it matters: Referral timing becomes clinically consequential when disease trajectory can outpace manufacturing, scheduling or transfer to a certified center.
54.9% select heavily pretreated relapsed or refractory patients as the population with the highest urgency for improved cellular therapy options. Earlier-line patients and older or frail patients each receive 15.7%, solid-tumor patients 11.8%, and rare subtypes 2.0%.
What the pattern suggests: The field’s expansion is important, but clinicians still see the sharpest immediate need in patients with few remaining alternatives.
Why it matters: This creates a tension: the patients with the greatest urgency may also have the least time and physiologic reserve to navigate a slow pathway.
29.4% most urgently want evidence on real-world effectiveness versus trial performance. Long-term survival and durability and optimal sequencing each receive 21.6%, biomarkers 15.7%, comparative effectiveness versus bispecific antibodies 7.8%, and quality of life or long-term safety 3.9%.
What the pattern suggests: The dominant evidence questions are translational: how the therapy performs in routine patients and where it belongs relative to rapidly evolving alternatives.
Why it matters: As treatment choices multiply, a therapy can be effective in isolation but still difficult to place without sequencing and comparative evidence.
For CRS and ICANS, 13.7% are extremely confident, 27.5% very confident, 35.3% moderately confident, 19.6% slightly confident and 3.9% not confident. For referral timing, 92.2% are at least moderately confident.
What the pattern suggests: Knowledge confidence is not the same as pathway capacity. Many clinicians know when they would like to refer and feel able to manage common toxicities, yet access can still break down operationally.
Why it matters: Education remains necessary, but additional education alone cannot solve transfer delays, manufacturing turnaround or patient travel constraints.
33.3% choose complex or slow referral workflows as the primary barrier, 25.5% choose manufacturing delay, 15.7% insurance or reimbursement, 11.8% intensive monitoring resources, 7.8% patient financial burden and 5.9% lack of nearby certified centers.
What the pattern suggests: The access chain is distributed across institutions. No single actor controls community referral, academic intake, manufacturing, payer approval, travel and post-infusion monitoring.
Why it matters: Improving one step can simply move the queue to the next unless the pathway is redesigned end to end.
33.3% select effective cellular therapies for solid tumors as the highest three-year priority. 23.5% prioritize community or outpatient administration, 19.6% improved safety profiles, 13.7% faster manufacturing, 5.9% reimbursement, and 3.9% head-to-head evidence versus bispecific antibodies.
What the pattern suggests: The top priorities move in two directions: broaden what cellular therapy can treat and broaden where it can be delivered.
Why it matters: Scientific expansion without delivery expansion can deepen access concentration, while decentralization without safety and manufacturing improvements can strain community capacity.
The survey suggests that the next cellular-therapy problem is not simply inventing another product. It is making the pathway faster, earlier and more connected. Oncologists see the highest urgency in heavily pretreated patients, but those patients are also most vulnerable to referral and manufacturing delay. The strategic challenge is therefore to align scientific progress with operational progress so that a therapy’s potential is not lost between eligibility, transfer, cell production and treatment.
Clinical context sources: National Cancer Institute: T-cell Transfer Therapy · National Cancer Institute: CAR T Cells · National Cancer Institute: Lifileucel · FDA prescribing information: CAR-T safety monitoring example. These FAQs provide general educational context and do not replace specialty guidance or patient-specific clinical judgment.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
